Impact of adalimumab on clinical outcomes, healthcare resource utilization, and sick leave in patients with ankylosing spondylitis: an observational study from five Central and Eastern European countries

Daniela Opris-Belinski MD, PhD, Shandor F Erdes MD, PhD, Simeon Grazio MD, PhD, Ladislav Šenolt MD, PhD, Maja Hojnik MD, PhD, Orsolya Nagy MD, PhD, Diana Marina BSc, Sándor Szántó MD, PhD, DSc

Article Type

Original Research

Published

This study assessed the impact of adalimumab on clinical outcomes, healthcare resource utilization, and sick leave in patients with ankylosing spondylitis in five Central and Eastern Europe countries.

Read more

The cost of biologics for psoriasis is increasing

Judy Cheng, Steven R Feldman

Article Type

Original Research

Published

Biologic agents have revolutionized the management of psoriasis but at a higher cost compared with “traditional” agents. Cost must be considered when evaluating management options for psoriasis. This piece of original research To estimates the annual cost of treatment of psoriasis using biologic agents and assess the trend over the past decade.

Read more

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.